The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $11.45 in the prior trading day, Dyne Therapeutics Inc (NASDAQ: DYN) closed at $10.46, down -8.65%. In other words, the price has decreased by -$8.65 from its previous closing price. On the day, 2.93 million shares were traded. DYN stock price reached its highest trading level at $10.9 during the session, while it also had its lowest trading level at $9.96.
Ratios:
Our goal is to gain a better understanding of DYN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.60 and its Current Ratio is at 15.60. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BMO Capital Markets on March 12, 2025, initiated with a Outperform rating and assigned the stock a target price of $50.
On March 07, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $50.
On December 13, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $46.Robert W. Baird initiated its Outperform rating on December 13, 2024, with a $46 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 13 ’25 when Friedl-Naderer Johanna sold 143 shares for $12.12 per share. The transaction valued at 1,733 led to the insider holds 96,057 shares of the business.
Scalzo Richard William sold 1,343 shares of DYN for $15,283 on Mar 11 ’25. The SVP, Head of Finance & Admin. now owns 122,330 shares after completing the transaction at $11.38 per share. On Mar 11 ’25, another insider, Beskrovnaya Oxana, who serves as the Chief Scientific Officer of the company, sold 2,153 shares for $11.38 each. As a result, the insider received 24,501 and left with 195,840 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DYN now has a Market Capitalization of 1295240832 and an Enterprise Value of 564969408.
Stock Price History:
The Beta on a monthly basis for DYN is 1.17, which has changed by -0.62428164 over the last 52 weeks, in comparison to a change of 0.077997446 over the same period for the S&P500. Over the past 52 weeks, DYN has reached a high of $47.45, while it has fallen to a 52-week low of $10.72. The 50-Day Moving Average of the stock is -20.77%, while the 200-Day Moving Average is calculated to be -63.33%.
Shares Statistics:
The stock has traded on average 2.10M shares per day over the past 3-months and 2003140 shares per day over the last 10 days, according to various share statistics. A total of 102.32M shares are outstanding, with a floating share count of 86.99M. Insiders hold about 23.10% of the company’s shares, while institutions hold 81.00% stake in the company. Shares short for DYN as of 1741910400 were 12383217 with a Short Ratio of 5.89, compared to 1739491200 on 10895395. Therefore, it implies a Short% of Shares Outstanding of 12383217 and a Short% of Float of 12.76.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Dyne Therapeutics Inc (DYN) is currently under the scrutiny of 10.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.85, with high estimates of -$0.66 and low estimates of -$1.06.
Analysts are recommending an EPS of between -$2.78 and -$4.37 for the fiscal current year, implying an average EPS of -$3.48. EPS for the following year is -$3.62, with 10.0 analysts recommending between -$3.0 and -$4.85.
